{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:17:11Z","timestamp":1792534631792,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.psychres.2026.117340","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T17:26:08Z","timestamp":1785086768000},"page":"117340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and Safety Outcomes of Different Plasma Clozapine and Norclozapine Levels in Schizophrenia Spectrum Disorder: A Dose-Response Meta-Analysis Exploring \u201ccritical\u201d Levels"],"prefix":"10.1016","volume":"365","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-0853","authenticated-orcid":false,"given":"Michele","family":"Fornaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0866-5270","authenticated-orcid":false,"given":"Chiara","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-5652","authenticated-orcid":false,"given":"Andrea","family":"de Bartolomeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2026.117340_bib0001","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.euroneuro.2024.04.012","article-title":"Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice","volume":"84","author":"Agid","year":"2024","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2026.117340_bib0002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0005","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15149","article-title":"Association Between Clozapine Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia","volume":"85","author":"Brainerd","year":"2024","journal-title":"The Journal of clinical psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117340_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/138920007780655469","article-title":"CYP-mediated clozapine interactions: how predictable are they?","volume":"8","author":"Chetty","year":"2007","journal-title":"Current drug metabolism"},{"issue":"1","key":"10.1016\/j.psychres.2026.117340_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14740338.2020.1698545","article-title":"The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy","volume":"19","author":"Costa-Dookhan","year":"2020","journal-title":"Expert Opinion on Drug Safety"},{"issue":"1","key":"10.1016\/j.psychres.2026.117340_bib0012","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12874-016-0189-0","article-title":"Dose-response meta-analysis of differences in means","volume":"16","author":"Crippa","year":"2016","journal-title":"BMC medical research methodology"},{"key":"10.1016\/j.psychres.2026.117340_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v072.c01","article-title":"Multivariate dose-response meta-analysis: the dosresmeta R package","volume":"72","author":"Crippa","year":"2016","journal-title":"Journal of Statistical Software"},{"issue":"18","key":"10.1016\/j.psychres.2026.117340_bib0100","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1080\/14656566.2022.2145884","article-title":"Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia","volume":"23","author":"de Bartolomeis","year":"2022","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.psychres.2026.117340_bib0018","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14740338.2024.2399094","article-title":"Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature","volume":"24","author":"De las Cuevas","year":"2025","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.psychres.2026.117340_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2025.112747","article-title":"Prescribing clozapine to 10% of patients with schizophrenia may save 320,000 lives and cost 2400 deaths from agranulocytosis","volume":"104","author":"de Leon","year":"2026","journal-title":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0101","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2019-100183","article-title":"Clozapine is strongly associated with the risk of pneumonia and inflammation","volume":"33","author":"de Leon","year":"2020","journal-title":"General psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2026.117340_bib0026","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FPC.0b013e328354026b","article-title":"Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A (TA) 7TAA and UGT1A4 L48V polymorphisms","volume":"22","author":"Erickson-Ridout","year":"2012","journal-title":"Pharmacogenetics and genomics"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0027","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1192\/bja.2022.71","article-title":"Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations","volume":"29","author":"Flanagan","year":"2023","journal-title":"BJPsych advances"},{"issue":"4","key":"10.1016\/j.psychres.2026.117340_bib0028","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/JCP.0000000000002007","article-title":"Plasma Clozapine in Treatment Refractory Schizophrenia: What Is the Target Range?","volume":"45","author":"Flanagan","year":"2025","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0033","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0006-3223(96)00298-3","article-title":"Clozapine-induced electroencephalogram changes as a function of clozapine serum levels","volume":"42","author":"Freudenreich","year":"1997","journal-title":"Biological Psychiatry"},{"issue":"7454","key":"10.1016\/j.psychres.2026.117340_bib0037","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Group","year":"2004","journal-title":"bmj"},{"key":"10.1016\/j.psychres.2026.117340_bib0102","doi-asserted-by":"crossref","DOI":"10.1055\/a-2860-7861","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects","author":"Hart","year":"2026","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2026.117340_bib0103","article-title":"High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting","author":"Hart","year":"2026","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0042","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2026.117340_bib0044","series-title":"Meta-analysis: from forest plot to network meta-analysis","first-page":"180","author":"Hwang","year":"2018"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0048","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.psychres.2026.117340_bib0113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2023.09.029","article-title":"Association between initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital","volume":"268","author":"Kang","year":"2024","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0114","doi-asserted-by":"crossref","first-page":"311","DOI":"10.30773\/pi.2023.0413","article-title":"Comparative Study of the Efficacy and Side Effects of Brand-Name and Generic Clozapine for Long-Term Maintenance Treatment Among Korean Patients With Schizophrenia: A Retrospective Naturalistic Mirror-Image Study","volume":"21","author":"Kang","year":"2024","journal-title":"Psychiatry Investigation"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0049","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia bulletin"},{"issue":"4","key":"10.1016\/j.psychres.2026.117340_bib0051","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: a systematic review and meta-analysis","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1016\/j.psychres.2026.117340_bib0052","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2026.117340_bib0054","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1016\/j.csda.2009.05.001","article-title":"A two-stage hierarchical regression model for meta-analysis of epidemiologic nonlinear dose\u2013response data","volume":"53","author":"Liu","year":"2009","journal-title":"Computational Statistics & Data Analysis"},{"issue":"10","key":"10.1016\/j.psychres.2026.117340_bib0057","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.psychres.2026.117340_bib0059","series-title":"The clozapine handbook: Stahl's handbooks","author":"Meyer","year":"2019"},{"issue":"21","key":"10.1016\/j.psychres.2026.117340_bib0062","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.3390\/jcm14217892","article-title":"Personalized Prediction of Clozapine Treatment Response Using Therapeutic Drug Monitoring Data in Japanese Patients with Treatment-Resistant Schizophrenia","volume":"14","author":"Nakahara","year":"2025","journal-title":"Journal of Clinical Medicine"},{"issue":"6","key":"10.1016\/j.psychres.2026.117340_bib0064","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1192\/bjp.2023.27","article-title":"Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis","volume":"222","author":"Northwood","year":"2023","journal-title":"The British Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0065","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological reports"},{"key":"10.1016\/j.psychres.2026.117340_bib0066","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"bmj"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0068","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-012-2922-7","article-title":"Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?","volume":"225","author":"Remington","year":"2013","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.psychres.2026.117340_bib0069","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/02698811251365177","article-title":"The pharmacology underlying the unique antipsychotic efficacy of clozapine","volume":"39","author":"Reynolds","year":"2025","journal-title":"Journal of Psychopharmacology"},{"issue":"2-3","key":"10.1016\/j.psychres.2026.117340_bib0071","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2012.08.018","article-title":"Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case\u2013control study","volume":"141","author":"Ronaldson","year":"2012","journal-title":"Schizophrenia research"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0072","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/JCP.0000000000001341","article-title":"European whites may need lower minimum therapeutic clozapine doses than those customarily proposed","volume":"41","author":"Schoretsanitis","year":"2021","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2026.117340_bib0073","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sjpmh.2023.10.001","article-title":"Obsessive\u2013compulsive symptoms and disorder in clozapine-treated schizophrenia","volume":"18","author":"Seow","year":"2025","journal-title":"Spanish Journal of Psychiatry and Mental Health"},{"key":"10.1016\/j.psychres.2026.117340_bib0075","article-title":"Intervention meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiology and health"},{"key":"10.1016\/j.psychres.2026.117340_bib0076","article-title":"Dose-response meta-analysis: application and practice using the R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiology and health"},{"issue":"8","key":"10.1016\/j.psychres.2026.117340_bib0077","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Molecular Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117340_bib0078","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine","volume":"29","author":"Sirot","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2026.117340_bib0079","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"The British Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2026.117340_bib0081","series-title":"Clozapine levels as a predictor for therapeutic response: a systematic review and meta-analysis","first-page":"422","author":"Siskind","year":"2021"},{"key":"10.1016\/j.psychres.2026.117340_bib0082","first-page":"366","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"bmj"},{"key":"10.1016\/j.psychres.2026.117340_bib0085","series-title":"R: A language and environment for statistical computing","author":"Team","year":"2023"},{"key":"10.1016\/j.psychres.2026.117340_bib0086","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euroneuro.2025.02.012","article-title":"Antipsychotic drug dosing and study discontinuation in schizophrenia: a systematic review and dose-response meta-analysis","volume":"94","author":"Tian","year":"2025","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2026.117340_bib0089","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Current drug metabolism"},{"key":"10.1016\/j.psychres.2026.117340_bib0091","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2018.05.046","article-title":"Prescriber and institutional barriers and facilitators of clozapine use: a systematic review","volume":"201","author":"Verdoux","year":"2018","journal-title":"Schizophrenia research"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0092","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1\u201312.5 years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophrenia bulletin"},{"key":"10.1016\/j.psychres.2026.117340_bib0095","unstructured":"Wells, G., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., 2000. The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. Ottawa, Canada: The Ottawa Hospital Research Institute; 2000."},{"key":"10.1016\/j.psychres.2026.117340_bib0096","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euroneuro.2023.03.015","article-title":"Antipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose-response meta-analysis","volume":"72","author":"Wu","year":"2023","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2026.117340_bib0097","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2023.10.001","article-title":"Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore","volume":"268","author":"Yang","year":"2024","journal-title":"Schizophrenia research"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0098","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0922-4106(94)90047-7","article-title":"Clozapine is a potent and selective muscarinic M4 receptor agonist","volume":"269","author":"Zorn","year":"1994","journal-title":"European Journal of Pharmacology: Molecular Pharmacology"},{"issue":"7","key":"10.1016\/j.psychres.2026.117340_bib0105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert review of clinical pharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2026.117340_bib0106","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/schbul\/sbaa060","article-title":"Clozapine combination and augmentation strategies in patients with schizophrenia\u2014recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group","volume":"46","author":"Wagner","year":"2020","journal-title":"Schizophrenia bulletin"},{"key":"10.1016\/j.psychres.2026.117340_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychires.2025.09.081","article-title":"A retrospective study on clozapine-induced blood dyscrasias in the first 20 weeks of therapy","author":"Ali","year":"2025","journal-title":"Journal of Psychiatric Research"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0108","doi-asserted-by":"crossref","DOI":"10.1002\/hup.70006","article-title":"Clozapine Once-Versus Multiple-Daily Dosing Regimen: A Single-Center, Retrospective, Cross-Sectional Study","volume":"40","author":"Ding","year":"2025","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"4","key":"10.1016\/j.psychres.2026.117340_bib0109","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00044011-200828040-00004","article-title":"Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia","volume":"28","author":"Golden","year":"2008","journal-title":"Clinical drug investigation"},{"issue":"6","key":"10.1016\/j.psychres.2026.117340_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287122","article-title":"Analysis of clozapine-induced seizures using the Japanese Adverse Drug Event Report database","volume":"18","author":"Hatano","year":"2023","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0111","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S1461145703003456","article-title":"The safety of clozapine in the treatment of first-and multiple-episode patients with treatment-resistant schizophrenia","volume":"6","author":"Hofer","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0112","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/JCP.0000000000001980","article-title":"The impact of therapeutic drug monitoring on clozapine dosing and clinical outcome in a Tertiary Care Center in India: a retrospective study","volume":"45","author":"Jogi","year":"2025","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/YIC.0000000000000255","article-title":"Association between electroencephalogram changes and plasma clozapine levels in clozapine-treated patients","volume":"34","author":"Kim","year":"2019","journal-title":"International clinical psychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0116","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","article-title":"Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms","volume":"28","author":"Lin","year":"2006","journal-title":"Therapeutic drug monitoring"},{"issue":"1","key":"10.1016\/j.psychres.2026.117340_bib0117","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1139\/jpn.0203","article-title":"Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations","volume":"27","author":"Llorca","year":"2002","journal-title":"Journal of Psychiatry and Neuroscience"},{"issue":"1","key":"10.1016\/j.psychres.2026.117340_bib0118","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00326-7","article-title":"Clozapine-induced weight gain predicts improvement in psychopathology","volume":"59","author":"Meltzer","year":"2003","journal-title":"Schizophrenia research"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0119","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.2023.44","article-title":"Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study","volume":"223","author":"Oloyede","year":"2023","journal-title":"The British Journal of Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2026.117340_bib0120","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1177\/02698811251355602","article-title":"Randomised controlled trial of clozapine in resistant schizophrenia and schizoaffective disorder","volume":"39","author":"Peraire","year":"2025","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0121","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"The American journal of psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2026.117340_bib0122","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1139\/jpn.0733","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"10.1016\/j.psychres.2026.117340_bib0123","article-title":"Adverse Reactions to Clozapine: Plasma Clozapine in Relation to Smoking Status","author":"Reeves","year":"2026","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2026.117340_bib0124","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.euroneuro.2020.05.011","article-title":"Causes of death in clozapine-treated patients in a catchment area: a 10-year retrospective case-control study","volume":"36","author":"Rose","year":"2020","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2026.117340_bib0125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2023.09.032","article-title":"Prevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia","volume":"268","author":"Sankaranarayanan","year":"2024","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2026.117340_bib0126","article-title":"Drug blood levels, influencing factors and their relationship with metabolic parameters in patients with schizophrenia using clozapine","author":"Sigan","year":"2025","journal-title":"Journal of Psychiatric Research"},{"issue":"11","key":"10.1016\/j.psychres.2026.117340_bib0127","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.156.11.1744","article-title":"Double-blind study of clozapine dose response in chronic schizophrenia","volume":"156","author":"Simpson","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117340_bib0128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002130050028","article-title":"Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics","volume":"148","author":"Spina","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2026.117340_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115539","article-title":"Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions","volume":"330","author":"Van der Horst","year":"2023","journal-title":"Psychiatry Research"},{"issue":"12","key":"10.1016\/j.psychres.2026.117340_bib0130","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1176\/ajp.153.12.1579","article-title":"Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges","volume":"153","author":"VanderZwaag","year":"1996","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2026.117340_bib0131","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/0706743716670128","article-title":"Genetic determinants of clozapine-induced metabolic side effects","volume":"62","author":"Vasudev","year":"2017","journal-title":"The Canadian Journal of Psychiatry"},{"issue":"2-3","key":"10.1016\/j.psychres.2026.117340_bib0132","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2006.01.011","article-title":"Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia","volume":"83","author":"Xiang","year":"2006","journal-title":"Schizophrenia research"},{"issue":"3","key":"10.1016\/j.psychres.2026.117340_bib0133","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/acps.13264","article-title":"The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study","volume":"143","author":"Yada","year":"2021","journal-title":"Acta Psychiatrica Scandinavica"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126004002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126004002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:23:15Z","timestamp":1788812595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126004002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":82,"alternative-id":["S0165178126004002"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117340","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety Outcomes of Different Plasma Clozapine and Norclozapine Levels in Schizophrenia Spectrum Disorder: A Dose-Response Meta-Analysis Exploring \u201ccritical\u201d Levels","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117340"}}